Coherus Oncology (CHRS) Total Debt (2013 - 2026)

Coherus Oncology has disclosed Total Debt across 14 years of filings, most recently posting $37.2 million for Q2 2026.

• In Q2 2026, Total Debt rose 1.03% year-over-year to $37.2 million; the TTM figure through Jun 2026 stood at $37.2 million (up 1.03% YoY), while the FY2025 annual figure was $37.1 million, down 26.37% from the prior year.
• Total Debt came in at $37.2 million for Q2 2026 at Coherus Oncology, roughly flat from $37.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $250.3 million in Q3 2023 to a low of $36.9 million in Q2 2025.
• Average Total Debt over 5 years is $139.6 million, with a median of $129.4 million recorded in 2022.
• Year-over-year, Total Debt soared 225.09% in 2022 and slumped 81.69% in 2024.
• Over 5 years, Total Debt stood at $245.5 million in 2022, then grew by 1.75% to $249.8 million in 2023, then sank by 79.86% to $50.3 million in 2024, then slipped by 26.37% to $37.1 million in 2025, then grew by 0.53% to $37.2 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $37.2 million in Q2 2026, $37.1 million in Q1 2026, and $37.1 million in Q4 2025.